The American journal of gastroenterology
Cure8 research brief
Why This Matters
People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which can inform patient counselling and shared decision-making.
Who Should Pay Attention
Adults with Crohn's disease (including treatment-naïve patients and those on thiopurines, anti-TNFs, vedolizumab, or ustekinumab), clinicians managing IBD, and researchers studying treatment safety and cancer risk.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study followed 38,733 patients with Crohn's disease and matched comparators for a median of 7.3 years. Treatment cohorts included new users of thiopurines, TNF inhibitors, combination thiopurine+TNFi, vedolizumab, ustekinumab, and treatment-naïve patients.
Cancer incidence was higher across all cohorts compared with the general population, with the largest absolute excess driven by non-melanoma skin cancer. When non-melanoma skin cancers were removed, the remaining excess amounted to roughly 1 additional cancer case per 1,000 person-years in several treatment groups.
The study used a "once-exposed-always-exposed" design and age-stratified incidence rate differences. Absolute risk differences increased with patient age.
Keep In Mind
Results come from Swedish registry data (2007–2023) and use an observational design; absolute risks were small and largely driven by non-melanoma skin cancers. The abstract-level summary does not replace the full article for methodological details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationThe American journal of gastroenterology
AuthorsÅsa H Everhov, Julia Eriksson, Jonas Söderling +7 more
InstitutionDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...